BeyondSpring shares surge 14.00% intraday after 85% DCR in NSCLC trial and SEED's $30M funding.

Beyondspring surged 13.99% intraday following the release of Q3 2025 results highlighting robust clinical data for Plinabulin, including an 85% disease control rate in metastatic NSCLC patients after PD-1/L1 inhibitors, and FDA/China NMPA clearance for SEED’s RBM39 degrader IND application. The announcement of SEED’s $30 million Series A-3 financing and its Prix Galien USA finalist status further underscored corporate progress. Strong Phase 3 DUBLIN-3 trial outcomes—showing extended survival and reduced chemotherapy-induced neutropenia—reinforced Plinabulin’s potential to advance care standards. These developments, coupled with improved financials (narrowed net loss and $12.5 million cash reserves), bolstered investor confidence in the company’s pipeline and strategic partnerships.